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Malignant mesothelioma is an incurable disease associated with asbestos exposure arising in the pleural cavity and less
frequently in the peritoneal cavity. Platinum-based combination chemotherapy with pemetrexed is the established stand-
ard of care. Multimodality approaches including surgery and radiotherapy are being investigated. Increasing knowledge
about the molecular characteristics of mesothelioma had led to the identiﬁcation of novel potential targets for systemic
therapy. Current evidence suggests pathways activated in response to merlin deﬁciency, including Pi3K/mTOR and the
focal adhesion kinase, as well as immunotherapeutic approaches to be most promising. This review elaborates on the ra-
tionale behind targeted approaches that have been and are undergoing exploration in mesothelioma and summarizes
available clinical results and ongoing efforts to improve the systemic therapy of mesothelioma.
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introduction
Mesothelioma is a fatal disease predominantly arising in the
pleural cavity and less so in the peritoneal cavity. The associ-
ation of mesothelioma with asbestos exposure is well estab-
lished. The time from exposure to the diagnosis is on the
average greater than 40 years, explaining why the disease inci-
dence is still raising in many countries despite working bans on
the use of asbestos in the early 1990s. Platinum-based chemo-
therapy, mostly combined with the folate antagonist peme-
trexed, is the established standard of care [1]. In earlier stages
of pleural mesothelioma, multimodality therapy including
extrapleural pneumonectomy or more recently extended pleur-
ectomy/decortication, with or without radiotherapy, are being
investigated in selected patients [2]. There is currently no
deﬁned standard for second-line therapy. The rationale behind
investigating novel targeted approaches, available results and
ongoing efforts are summarized in this review.
exploring molecular alterations
Data mining of version 71 of the catalog of somatic mutations
in cancer (COSMIC, http://www.sanger.ac.uk/cosmic) reveals
that the genes that are most frequently mutated in malignant
pleural mesothelioma are ‘cyclin-dependent kinase inhibitor
2A’ (CDKN2A), ‘neuroﬁbromatosis type 2’ (NF2) and BRCA-
‘associated protein 1’.
targeting the cell cycle
Mesothelioma lack expression of both CDKN2A encoded proteins
p16 and ARF due to gene deletion or methylation (reviewed in
[3]). Deletion in CDKN2A leads to loss of control of cyclin
D-dependent kinases (CDK). Although CDK4/6-speciﬁc inhibi-
tors are under investigation in clinical trials, animal models with
CDKN2A deﬁciency showed that loss of CDKN2A function is
not necessarily associated with CDK4/6 addiction [4].
Although only a minor fraction of mesothelioma presents
with p53 mutations [5], this lead to the hypothesis that this
tumor might be dependent on G2 checkpoint and therefore vul-
nerable to a G2 checkpoint inhibition when combined with
chemotherapy. In line with this hypothesis, the calmodulin-
binding peptide (CBP501) was clinically tested in combination
with cisplatin and pemetrexed in order to increase the sensitivity
of mesothelioma cells to chemotherapy [6]. In patients receiving
CBP501 with chemotherapy PFS of more than 4 months was
achieved compared with 39% receiving chemotherapy alone
(Table 1) [7].
targeting NF2/Hippo deﬁciency
The NF2/Hippo signaling pathway has been shown to be disrupted
in most mesothelioma [5, 8] characterized by mutation or inactiva-
tion of the NF2 gene (reviewed in [3]). Experimental animal
models indicate that this event, together with a deﬁciency in
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Table 1. Clinical trials investigating targeted therapy in mesothelioma
Target Clinical trial
ID
Experimental arm Mechanism Control arm Phase Primary end points Expected completion
date
Chemotherapy
sensitizer
NCT00700336 CBP501 plus Cis/Pem G2 checkpoint inhibition Cis/Pem I/II Safety, MTD, PFS Completed
Altered NF2 signaling NCT01138033 GSK2256098 Focal adhesion kinase inhibitor I MTD December 2014
NCT01870609 VS-6063 Focal adhesion kinase inhibitor Placebo II OS, PFS December 2016
NCT02004028 VS-6064 Focal adhesion kinase inhibitor II PK November 2014
Altered NF2 signaling NCT00854152 GDC-0980 PI3K/mTOR inhibitor I PK, MTD August 2014
NCT01655225 LY3023414 PI3K/mTOR inhibitor I Recommended phase II
dose
September 2014
Altered NF2 signaling NCT00770120 Everolimus mTOR inhibitor II PFS, RR completed
NCT01024946 Everolimus mTOR inhibitor II PFS, RR completed
Arginine dependency NCT01279967 Pegylated arginine deiminase Growth inhibition of ASS-negative tumors Best supportive
care
II PFS January 2014
Receptor tyrosine
kinases
NCT00402766 Imatinib mesylate plus Cis/
Pem
bcr/abl, c-kit, and PDGFR TKI I MTD August 2015
NCT00703638 Sorafenib plus Cis/Pem VEGFR2, VEGFR3, Raf, PDGFR, and
c-kit TKI
I MTD Completed
NCT01064648 Cediranib plus Cis/Pem VEGFR 1–3 Placebo (phase II) I/II MTD June 2014
NCT00700336 Dasatinib Src inhibition and PDGFR TKI I Modulation of p-Src
Tyr419
March 2016
NCT01592383 Erlotinib EGFR TKI II RR June 2015
NCT00459862 Pazopanib VEGFR1–3, PDGFR, and c-Kit II PFS Completed
NCT01211275 Axitinib pan-VEGFR inhibitor Cis/pem I/II Safety/efficacy Unknown
NCT01861301 Tivantinib MET inhibitor II ORR February 2015
NCT02049060 Tivantinib plus Carbo/Pem MET inhibitor I DLTs July 2014
NCT01590160 Ganetespib plus Cis/Pem Hsp90 inhibitor I/II DLTs December 2015
NCT01307100 Nintedanib plus Cis/Pem VEGFR, PDGFR, and FGFR TKI Cis/Pem II PFS May 2016
NCT01769547 Dovitinib FGFR3 inhibitor II PFS June 2016
Proteasome NCT00996385 Bortezomib and oxaliplatin Proteasome inhibitor II RR September 2013
Aminopeptidase N NCT01358084 NGR-hTNF TNF targeting tumor blood vessels Best supportive
care
II PFS June 2013
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cyclin-dependent kinase activator inhibitor (CDKN2A), is essential
for mesothelioma development. Therefore, targeting molecules
involved in the NF2/Hippo pathway is of major interest (Figure 1)
for the treatment of mesothelioma. NF2 is an upstream regulator
of the so-called Hippo signaling cascade, [9] which controls the
transcriptional co-activator Yes-associated protein (YAP). The dys-
function of Hippo pathway, which leads to increased YAP activity
[10], induces oncogenic transformation by the activation of tran-
scription factors including transcription enhancer activation
domain (TEAD) family members [11]. Upon binding TEADs,
YAP/TAZ upregulates the expression of several growth promoting
factors. YAP is constitutively active in more than 70% of primary
mesotheliomas [8, 12]. Hedgehog signaling has a role in maintain-
ing YAP protein stability in progenitor cells [13] and is activated in
mesothelioma, consistent with the re-activation of a signaling
known to be essential during embryonic mesothelial development
[14]. Treatment of mesothelioma xenografts with the hedgehog an-
tagonist HhAntag led to a decrease of the tumor volume accom-
panied by a decrease in Ki-67 labeling index.
Another possible approach is the direct inhibition of YAP ac-
tivity. Three compounds related to porphyrin that could inhibit
the transcriptional activity of YAP in vitro were identiﬁed by
screening of a Johns Hopkins Drug Library [15]. One of these,
verteporﬁn, in clinical use as a photosensitizer in photocoagula-
tion therapy for macular degeneration, was moderately effective
at blocking mouse Yap1-overexpression- or loss of Nf2-driven
hepatic tumorigenesis. These data suggest further investigation
of these compounds as anticancer therapies.
NF2 suppresses tumorigenesis by migrating into the nucleus
where it inhibits the E3 ubiquitin ligase CRL4 and through that
controls a subset of Hippo pathway target genes [16]; therefore,
CRL inhibitors such as MLN4924 should be investigated in
mesothelioma.
Interestingly, expression of constitutively active YAP causes
widespread miRNA suppression [17]. Thus, the Hippo pathway
may be responsible for the widespread miRNA repression
observed in cancer, including mesothelioma. To overcome the
difﬁculties of directly delivering miRNA mimics, minicells com-
posed of achromosomal bacterial cells and targeted by bispeciﬁc
antibodies have been developed. These have been used to restore
miR16 and induce growth arrest in mesothelioma xenografts
[18]. Minicells can be given safely to patients with advanced
cancer [19] and a clinical trial has started in mesothelioma
(ACTRN12614001248651).
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Figure 1. Genetic/epigenetic changes present in mesothelioma offer different possibilities for therapeutic intervention. Functional inactivation of NF2 and
NF2/Hippo pathway offers the opportunity to intervene using focal adhesion kinase (FAK) inhibitors, PI3/mTOR dual inhibitors, microtubule stabilizing
agents, E3 ubiquitin ligase CRL4/DCAF inhibitors, tumor suppressor miR delivery, inhibitors of the interaction between YAP and TEAD transcription activa-
tors, and 7 transmembrane G-coupled receptors (7TMGCPR) inhibitors regulating YAP activity. Auxotrophy for arginine render the tumor sensitive to the ac-
tivity of arginine deiminase. Calretinin-dependent survival can be blocked by calretinin silencing.
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targeting NF2-associated cytoskeletal alterations
In a systematical screen for tumor suppressors whose functional
inactivation would result in microtubular instability, NF2 was
identiﬁed as a microtubule stabilizer [20], demonstrating that
the microtubular network might be signiﬁcantly affected in
mesothelioma. Based on this and in vitro studies, epothilone B
would be a candidate for clinical evaluation [21].
NF2 alterations result also in activation of the focal adhesion
kinase (FAK) and merlin deﬁciency predicts for sensitivity to
FAK inhibitors [22, 23]. The underlying mechanism is that sur-
vival and proliferation signals seem mediated through extracel-
lular matrix-integrin signals promoting FAK activation in
mesothelioma cells with inactivating NF2 mutations [23]. There
is a phase I and two phase II trials ongoing testing the FAK inhi-
bitors GSK2256098 and defactinib (VS-6063) in mesothelioma
(Table 1). Determination of the NF2 status in these trials will
allow exploring whether the clinical outcome is indeed asso-
ciated with alteration of NF2.
targeting PI3K/mTOR
PI3K/mTOR signaling is activated in mesothelioma [24]. For the
time being, the reason for this has not been elucidated, as neither
PI3K nor receptor tyrosine kinase mutations/ampliﬁcations have
been found in two recent high-throughput studies [5, 25]. NF2-
null cells were shown sensitive to growth inhibitory effects of
rapamycin [26] via mechanisms involving PI3K signaling-inde-
pendent mammalian target of rapamycin complex (mTORC1)
activation. However, preliminary results of a phase II trial [27] of
the mTOR inhibitor, everolimus, did not show to be active in
unselected MPM patients (Table 1). In addition, a peritoneal
mesothelioma model was recently generated by deﬁciency in p53
and the tuberous sclerosis gene, a negative regulator of mTORC
[28]. GDC-0980 is a small molecule inhibitor of class I PI3K and
mTOR (mTORC1 and mTORC2) [29] has been tested in phase I
studies (Table 1) and the preliminary result of the phase I exten-
sion cohort showed two objective responses among 26 patients
with mesothelioma [30]. Another dual PI3K/mTOR inhibitor,
LY3023414 is tested in a phase I trial (Table 1).
synthetic lethal approaches
A large proportion of mesothelioma [31] show reduced expres-
sion of arginosuccinate synthetase-1, the rate-limiting enzyme
for arginine biosynthesis, rendering cells auxotrophic for argin-
ine and consequently susceptible to the arginine degrading
enzyme arginine deiminase (Adi-PEG20). Preliminary results of
a randomized phase II study (Table 1) showed a signiﬁcant PFS
improvement delivering ADI-PEG20 versus best supportive care
[32]. Almost all epithelioid and ∼50% of sarcomatoid meso-
thelioma express calretinin [33] which is widely used as a robust
diagnostic mesothelioma marker. Since its silencing inhibits
mesothelioma cell survival in vitro, this may offer another op-
portunity for a therapeutic intervention [34].
tyrosine kinase inhibitors
Deregulated expression of growth factors or proteins involved
in downstream signaling pathways has been shown to play an im-
portant role in malignant transformation of mesothelial cells.
Molecular studies in malignant pleural mesothelioma have con-
ﬁrmed that growth factors such as vascular endothelial growth
factor (VEGF), platelet-derived growth factor receptor beta
(PDGFRβ) and the epidermal growth factor receptor family are fre-
quently activated. Several clinical trials have tried to exploit these
speciﬁc characteristics using tyrosine kinase inhibitors (TKIs).
multitarged TKIs
Overexpression of platelet-derived growth factor (PDGF) has
been observed and found to be associated with a poor prognosis
[35]. While normal mesothelial cells express predominantly the
PDGFRα subunit and less PDGFRβ, mesothelioma was shown
to overexpress PDGFRβ [36]. In vitro studies show that VEGF
stimulates the growth of mesothelioma cells and anti-VEGF
rabbit polyclonal antibodies inhibit their growth [37–39].
The co-expression of c-kit in 26% [40] of mesothelioma has
inspired the use of imatinib, an inhibitor of bcr/abl, c-kit, and
PDGFRα and β. Four phase II clinical trials of imatinib as a
single agent in mesothelioma have been published. Of a total of
94 patients treated, no objective response was seen and progres-
sion-free survival was less than 2 months [41–44].
Sorafenib is a potent inhibitor of VEGFR2, VEGFR3, Raf,
PDGFRβ, and c-kit. In a phase II trial with 50 patients assessable
for response, 3 partial responses and 27 disease stabilizations
were observed, results deemed insufﬁcient for further evaluation
of sorafenib [45]. Another phase II trial assessed sorafenib in a
single-arm phase II study enrolling 53 patients using a Simon’s
two-stage design. Treatment was well tolerated and demonstrated
a moderate activity with a median PFS of 5.1 months [46].
Sunitinib, a VEGFR1, VEGFR2, VEGFR3, PDGFRβ, and c-kit
TKI was tested in a phase II trial in 53 patients resulting in partial
responses in 6 and stable disease in 34. An accompanying bio-
marker study was unsuccessful [47]. Another phase II trial using
a Simon’s two-stage design and a primary outcome of objective
response rate did not meet the criteria for continuing to the
second stage of accrual, with only one partial response observed
among 35 patients [48]. A phase I trial with an expansion cohort
in mesothelioma patients demonstrated that sunitinib was not
well tolerated at 37·5 mg with standard pemetrexed and cisplatin
doses, requiring dose reductions mainly due to cumulative myelo-
suppression and subsequent limited activity [49].
Pazopanib, a broad antiangiogenic broad TKI targeting
VEGFR1-3, PDGFRα and β, and c-kit, has been evaluated in a
phase II trial as a single agent in 34 mesothelioma patients result-
ing in a 6-month progression-free survival of 48% (Table 1).
Vatalanib targets VEGFR1, VEGFR2, c-kit, PDGFRβ, and c-Fms.
It was tested in a phase II trial and did not achieve the protocol-
speciﬁed 3-month PFS, ending its development mesothelioma
[50]. Cediranib is a VEGFR 1–3 TKI. Two phase II trials were
able to show only a modest single-agent activity with partial re-
mission in 4 and 5 patients out of 54 and 51 patients, respectively,
however with signiﬁcant toxicities [51, 52].
Dasatinib is an inhibitor of the Src family of nonreceptor tyro-
sine kinases and PDGFRβ. Single-agent dasatinib did not show any
activity in mesothelioma and was associated with inacceptable pul-
monary toxicities in a phase II trial enrolling 46 patients [53].
While the results from most of these trials were considered as
negative, the fact remains that activity of cediranib, imatinib,
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sunitinib, or sorafenib was observed in a low proportion of
patients, suggesting a need for the identiﬁcation of predictive
biomarkers to support further development. However, given the
multitargeted nature of these TKIs and the difﬁculties encoun-
tered in identifying biomarkers for antiangiogenic therapies in
general this will unlikely be successful.
Due to the few responses to TKIs, combinatorial regimens
with chemotherapy are ongoing. To this end, a study with cedir-
anib in combination with chemotherapy is currently recruiting
(Table 1) and another trial phase I/II trial has been randomizing
patients to cisplatin and pemetrexed with or without axitinib,
a pan-VEGFR inhibitor (Table 1). Several trials combining
chemotherapy with multitargeted TKIs are still being discussed
or currently in phase I (Table 1).
restricted TKI
Erlotinib and geﬁtinib are ﬁrst-generation TKIs targeting specif-
ically EGFR. EGFR expression has been demonstrated by immu-
nohistochemistry in 70%–95% of mesothelioma specimens and
its overexpression might be associated with a favorable progno-
sis [54–56]. Despite some encouraging in vitro data, phase II
trials in patients with untreated mesothelioma using geﬁtinib or
erlotinib have failed to demonstrate signiﬁcant activity. Geﬁtinib
demonstrated partial remissions in 2 of 43 untreated patients
[56]. Erlotinib was ineffective in 63 untreated patients despite
high expression of EGFR in patients’ tumors. Here, the activa-
tion of the PI3K/Akt downstream pathways was proposed as a
potential mechanism of primary resistance [57]. Also the com-
bination of erlotinib and bevacizumab after platinum-based
chemotherapy did not result in any responses among 24 meso-
thelioma patients [58].
Other targets including MET- and FGFR3-TKIs, tiventanib,
and dovitinib, are under investigation (Table 1).
histone deacetylase inhibitors
The equilibrium between the acetylated and deacetylated forms
of histone proteins is regulated by histone acetyltransferase and
histone deacetylase (HDAC). HDAC inhibitors will alter the
wrapping DNA around histones, modify the access of transcrip-
tion factors and consequently impact the expression of various
genes.
After two promising phase I trials including small numbers of
mesothelioma treated by vorinostat as monotherapy or com-
bined with chemotherapy, [59] a placebo-controlled phase III
trial including 660 mesothelioma patients who had progressed
after treatment with pemetrexed and platinum was launched.
Results were reported at ECCO-ESMO 2011 and were negative
for all end points [60]. Another small phase II trial with the
HDAC inhibitor belinostat was also negative [61].
In vitro data suggested that valproic acid might have a proa-
poptotic effect in synergy with doxorubicine. A phase II trial
evaluating valproic acid in combination with doxorubicine in 45
patients pretreated with chemotherapy demonstrated objective
responses in seven with a median progression-free survival of
2.5 months [62].
proteasome inhibitors
Bortezomib was found to be inactive in a single-arm phase II
trial in poor performance status ﬁrst-line and second-line meso-
thelioma patients with only one conﬁrmed response of 33
patients [63]. Bortezomib was also evaluated in combination
with cisplatin in a prospective phase II trial with progression-
free survival rate at 18 weeks as primary end point [64]. Eighty-
two patients were treated with an 18-week progression-free sur-
vival of 53%. Based on statistical assumptions, the null hypoth-
esis could not be rejected and the combination was considered
not worthy of further investigation.
bevacizumab
A randomized phase II trial of untreated mesothelioma patients
compared cisplatin-gemcitabine alone or with bevacizumab. The
addition of bevacizumab did not improve response, progression-
free survival, or overall survival compared with chemotherapy
alone. A potential beneﬁt in patients with low circulating levels of
VEGF was suggested in subgroup analysis [65]. Another phase II
trial combined treatment of cisplatin and pemetrexed with beva-
cizumab in 45 inoperable chemotherapy naïve mesothelioma
patients. The response rate of 41%, median PFS of 6.9 months,
and median OS 15.3 months were reported, with development
of hypertension as a possible surrogate marker for bevacizumab
activity [66].
A two-armed phase II/III trial compared the standard of care
cisplatin and pemetrexed regimen with or without bevacizumab
as ﬁrst-line treatment and maintenance in inoperable mesotheli-
oma patients. While tolerance was good, the preliminary ana-
lysis of the study revealed that disease control at 6 months
favored the bevacizumab arm (73.5% and 43.2%, P = 0·010).
Final results of this trial are eagerly awaited [67].
other antiangiogenic interventions
vascular disrupting agents
BNC105P is a small molecule inhibiting tubulin polymerization
that functions as a vascular disrupting agent through selectively
shutting down tumor blood vessels without affecting normal vas-
culature. Preclinical models have demonstrated signiﬁcant tumor
growth suppression and regression with BNC105P [68].VDA
BNC105P was tested as a second-line treatment in advanced
mesothelioma and proven ineffective in a trial of 30 patients [69].
thalidomide
Thalidomide is the oldest and perhaps the most extensively
studied drug classiﬁed as an antiangiogenic agent, which activity
is attributed to the inhibition of VEGF, basic ﬁbroblast growth
factor, as well as Transforming growth factor-β (TGF-β) and
tumor necrosis factor (TNF)-α [70, 71]. A phase I trial explored
its activity in 40 mesothelioma patients, a third of them being
treatment naive. There were no responders, with an OS of 7.6
months and 11 were free of progression after 6 months [72].
Two parallel unpublished phase II studies evaluated thalidomide
in combination with gemcitabine/cisplatin or thalidomide as a
single agent. Thirty-one chemotherapy naïve patients received
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thalidomide and gemcitabine/cisplatin with partial responses in
14% and an OS of 11 months [73]. Twenty-seven patients pre-
treated or unsuitable for chemotherapy were treated with single-
agent thalidomide. Responses occurred in 6% of the patients,
and OS was 11 months.
The utility of thalidomide in mesothelioma as maintenance
therapy for up to 1 year was evaluated in a large randomized
phase III trial in 222 patients who had not progressed after 4–6
cycles of pemetrexed with or without platinum. The primary
end point of time to progression was of 3.6 months in the
experimental arm when compared with 3.5 months in the
placebo arm, demonstrating the absence of beneﬁt of thalido-
mide maintenance [74].
NGR-hTNF
NGR-hTNF consists of human tumor necrosis factor-α (hTNF-α)
fused to the tumor-homing peptide asparagine-glycine-arginine
(NGR) able to selectively bind an aminopeptidase N isoform over-
expressed on tumor blood vessels. Based on an exploratory phase
II trial in mesothelioma, a phase III trial comparing NGR-hTNF to
best supportive care is ongoing [75].
immunotherapeutic approaches
In mesothelioma, a chronic inﬂammatory response represented
by inﬁltrating lymphocytes and plasma cells was associated with
a better prognosis [76]. As in other tumors, immunotherapeutic
strategies aimed at balancing the immune system in favor of an
anti-mesothelioma response are being explored (Figure 2).
transforming growth factor-β
TGF-β is a pleiotropic cytokine which can be produced by
cancer, stroma, and immune cells [77–79]. TGF-β attenuates the
antitumor immune response blocking priming and effector
phase of tumor-speciﬁc T cells. Fresolimumab (GC1008), a
humanized monoclonal antibody neutralizing active forms of
TGF-β, has been examined in a phase I trial in 13 patients with
mesothelioma [80]. No objective response was seen, but three
patients had stable disease at 3 months and ﬁve patients devel-
oped an enhanced antibody response to mesothelioma lysates
(Table 2).
interferon-β/interferon-α
Interferon-β (IFN-β) is type 1 cytokine with multiple functions
resulting in antiviral, antiproliferative, antiangiogenic activity
and immune cell stimulation. IFN-β has been delivered by an
adenoviral vector into the pleural effusion of patient with meso-
thelioma in two phase I trials, using one or two injections [81,
82]. Both trials found a transient increase of IFN-β in the
pleural cavity, mitigated by a neutralizing antibody response
resulting in clearance of the adenovirus and decrease of IFN-β.
There were no safety issues and antibody responses against the
mesothelin could be induced in some patients. Of the 13
patients treated, 4 had stable disease as the best response.
IFN-α can promote the differentiation and activity of host
immune cells and moreover correlates with generation of a
durable antitumor response [83]; one clinical study exploring
the efﬁcacy of this cytokine in mesothelioma showed a response
in ∼30% of patients when associated with chemotherapy,
however with major toxicity [84]. One phase I trial have shown
potential therapeutic beneﬁt of IFN-α 2a gene transfer mediated
by an adenoviral vector [85] and a new study with this approach
is still ongoing (see Table 2).
intrapleural viruses
Viruses are strong stimulants to the immune system by the acti-
vation of the innate as well as the adaptive responses. The
measles virus is oncolytic, resulting in tumor cell death and
antigen release, allowing T-cell priming through dendritic cells.
Also, immunoadjuvant properties of the measles virus were
shown by loading dendritic cells with measles-infected meso-
thelioma cells, which resulted in dendritic cell maturation [86].
Phase I clinical trials are under way testing the intrapleural
application of measles, herpes, and vaccinia virus in patients
with malignant pleural mesothelioma (Table 2).
immune checkpoint inhibition
Cancer cells often inhibit T-cell activation to escape immune sur-
veillance. After activation T cells express the cytotoxic T-lympho-
cyte antigen 4 (CTLA-4). When CTLA-4 binds members of the
B7 family the T-cell response becomes abrogated [87]. Blocking
monoclonal antibodies have been developed to prevent the nega-
tive feedback loop via CTLA-4. Tremelimumab, is a humanized
monoclonal IgG2 antibody binding to CTLA-4. Tremelimumab
has been tested as second line in mesothelioma in a phase II trial
[88]. Two of 29 patents had durable partial responses. Although
the primary end point of the study was not met, the disease
control rate of 31% and progression-free survival of 6 months
prompted further evaluation in an ongoing randomized phase II
study (Table 2).
Expression of PD-L1 allows cancers to evade the host immune
system by interaction with PD1. Treatment with antibodies tar-
geting these molecules has resulted in extraordinary responses for
advanced melanoma and lung cancer. Recently, the expression of
PD-L1 has been demonstrated in mesothelioma [89]. Therefore,
therapies targeting this pathway are of major interest and under
development for mesothelioma patients.
mesothelin
Mesothelin is a cell surface glycoprotein expressed in mesothe-
lial and peritoneal cells. Even if the biological function of
mesothelin it not fully understood, it is known that mesothelin
binds to CA-125 and is involved in cell adhesion (reviewed in
[90]). Amatuximab is a chimeric IgG1 antibody targeting
mesothelin. Studies demonstrated that it blocks the binding of
mesothelin to CA 125 and thus could be used also as a strategy
to prevent tumor metastasis [91]. Amatuximab was well toler-
ated in a phase I trial [92] and currently is tested in phase II in
patients with mesothelioma (Table 2). Antibodies can be used
to deliver cytotoxic agents to antigen expressing malignant cells.
The potent bacterial toxin Pseudomonas exotoxin A (PE38) was
linked to a disulﬁde-stabilized variable fragment based on the
afﬁnity modiﬁed variable light and heavy chain of amatuximab
(SS1(dsFv)PE38) and showed preclinical activity [93]. SS1(dsFv)
PE38 is under clinical investigation and was shown to be safe in
two phase I trials, in which 16 patients with mesothelioma were
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treated. Only minor antitumor activity could be observed.
Additionally, the development of neutralizing antibodies was
observed in 24% of patients prevented its use for more than one
cycle [94]. In a subsequent pilot study using immunosuppres-
sive pretreatment with pentostatin and cyclophosphamide to
prevent neutralizing antibodies and allow delivery of more
courses of treatment, 3 of 10 assessable patients had major
responses [95].
MF-T is a fully humanized anti-mesothelin antibody conju-
gated to microtubule-targeting toxophore DM4 (BAY 94-9343).
It showed selective cytotoxicity against mesothelioma cells,
while sparing normal mesothelial cells, and potent in vivo activ-
ity against cell line and tumor xenografts [96]. This compound
is thus a likely relevant candidate for further clinical testing.
In contrast to these described passive immunological inter-
ventions mesothelin can be targeted by active-speciﬁc vaccin-
ation. Live-attenuated Listeria vaccine expressing mesothelin
has been tested in a phase I study with mesothelin-expressing
tumors. CRS-207 was well tolerated and mesothelin-speciﬁc
CD8T-cell responses were detected [97]. Recent data, presented
at ASCO 2014, showed that CRS-207 can be safely combined
with standard of care chemotherapy and showed encouraging
antitumor activity with 9 of 15 subjects having conﬁrmed
durable partial response and 4 stable disease (Table 2).
Wilms tumor suppressor gene 1
The Wilms tumor suppressor gene 1 (WT1), is a transcription
factor highly expressed in mesothelioma and WT1 immunohis-
tochemistry is among the routine procedures used for the diag-
nosis of mesothelioma. WT1 peptides are immunogenic and
induce T-cell responses against mesothelioma cell lines [98]. In
a ﬁrst clinical trial class I and II, WT1 peptides were used for
vaccination with s.c. GM-CSF, which is used to mature dendritic
cells to augment T-cell priming. Of 9 patients with mesotheli-
oma treated, one remained without progression after 3 years
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Figure 2. Interplay of the immune system with malignant mesothelioma and possible immunotherapeutic interventions. Malignant mesothelioma cells
express tumor antigens such as WT1, FAP, mesothelin. Tumor antigens or other components from the malignant cells can be picked up by dendritic cells and
presented to T cells inducing a T-cell response. However, molecules like TGF-β can block T-cell priming in the lymph node or T-cell function in malignant
tissue. T-cell function can be also abrogated by activation of CTLA-4 and PD-1 on primed T cells. In addition, effector T cells can be converted in immunosup-
pressive regulatory T cells. Dendritic cell and re-directed T cells can be adoptively transferred. Dendritic cells loaded with peptides derived from tumor antigen
induced T-cell responses. To enhance priming, GM-CSF is given in combination with dendritic cells. To circumvent T-cell priming, re-directed effector T cells
can be transferred. IFN-γ is used to augment MHC expression on tumor cells increasing immunogenicity.
Volume 26 | No. 8 | August 2015 doi:10.1093/annonc/mdv101 | 
Annals of Oncology reviews
Table 2. Clinical trials investigating immunotherapy in mesothelioma
Target Clinical trial
ID
Experimental arm Mechanism Control arm Phase Primary end
points
Expected
completion
date
Immunosuppressive
cytokine
NCT01112293 Anti-TGF-βmonoclonal
antibody (GC1008)
Blocking TGF-β II PFS October 2012
Immunomodulating
cytokine
NCT01212367 Gene transfer IFN-α2a Immunomodulating cytokine I Safety December
2027
Immunoadjuvant NCT01503177 Intrapleural measles virus Dendritic cell maturation; oncolytic virus I Safety September
2014
NCT01721018 Intrapleural herpes virus Oncolytic virus I/II Safety, PFS April 2014
NCT01766739 Intrapleural vaccinia virus
(GL-ONC1)
Oncolytic virus I Safety January 2015
Immune checkpoint NCT01843374 Tremelimumab Blocking CTLA-4 Placebo II OS May 2016
Tumor-antigen passive NCT00738582 MORAb-009 (Amatuximab) Anti-mesothelin monoclonal antibody with
pemetrexed and cisplatin
II PFS November
2014
Tumor-antigen active-
specific
NCT01675765 CRS-207 live-attenuated Listeria
vaccine expressing mesothelin
Active-specific immune response against
mesothelin followed pemetrexed and
cisplatin
I Safety December
2015
NCT01265433 WT-1 analog peptide vaccine
plus GM-CSF
Adjuvant, active-specific immune response
against WT-1
Montanide
adjuvant + GM-CSF
II PFS December
2014
NCT01890980 WT-1 analog peptide vaccine
plus GM-CSF
Adjuvant, active-specific immune response
against WT-1
Montanide
adjuvant + GM-CSF
II PFS December
2017
NCT01258868 Autologous tumor cell vaccine Active-specific immune response against
autologous tumor cells in combination with
celecoxib and ISCOMATRIX
I Safety November
2018
NCT01143545 Allogeneic tumor cell vaccine Active-specific immune response against
allogeneic tumor cells in combination with
cyclophosphamide and celecoxib
I Safety May 2017
NCT01569919 TroVax: pox virus specific for
antigen 5T4
Pox virus carrying the 5T4 antigen plus
Cis/Pem
II Immune
responses to
5T4, safety
June 2014
NCT00280982 Tumor lysate-loaded autologous
dendritic cells
Active-specific immune response against
autologous tumor cells
I Safety Completed
Tumor-antigen active-
specific adoptive transfer
NCT01241682 Tumor lysate-loaded autologous
dendritic cells low-dose
cyclophosphamide
Active-specific immune response against
autologous tumor cells
I Safety Completed
Tumor-antigen adoptive
transfer
NCT01583686 Adoptive transfer of mesothelin-
specific re-directed T cells
T-cell response I/II Safety/PFS March 2019
NCT01355965 Adoptive transfer of mesothelin-
specific re-directed T cells
T-cell response I Safety May 2014
NCT01722149 Adoptive transfer of FAP-specific
re-directed T cells
T-cell response I Safety May 2015
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and ﬁve were documented to have a CD8 T-cell response [99].
Currently, randomized phase II trials with this vaccine are
ongoing in patients after completion of multimodality therapy
(Table 2).
vaccination with tumor cell lysate
Mesothelioma cell lysates are used for vaccination and can induce
an antitumoral response. Twenty-two patients were treated with
autologous tumor cell lysates and GM-CSF. In 32% of the
patients, an immune response could be induced, but there was no
objective response [100]. One clinical phase I trial is testing an
autologous tumor cell vaccine with an adjuvant (ISCOMATRIX)
and celecoxib to augment antigen presentation. The tumor cell
vaccine is exposed ex vivo to demethylating agents to increase
expression of tumor antigens (Table 2). Another phase one trial
evaluates an allogeneic tumor cell vaccine (K526-GM) in com-
bination with cyclophosphamide and celecoxib (Table 2).
Cyclophosphamide is intended to eradicate regulatory T cells,
which can inhibit dendritic cells to prime effector T cells [101].
Celecoxib is a COX-2 inhibitor resulting in decreased prostaglan-
din E2 (PGE2) and was used to block PGE2-mediated conversion
of regulatory T cells and to allow dendritic cell maturation [102].
cellular therapy
Adoptive transfer of dendritic cells pulsed ex vivo with tumor anti-
gens led to the ﬁrst FDA approved cellular therapy (Sipuleucel-T)
in prostate cancer [103]. In mesothelioma, a comparable approach
was tested in 10 patients vaccinated with autologous dendritic cells.
Each vaccine was composed of mature dendritic cells pulsed with
autologous tumor lysate [104]. In four patients, dendritic cell vac-
cination induced cytotoxic T cells. Results from a trial evaluating
dendritic cell-based vaccination in combination with low-dose
cyclophosphamide are awaited (Table 2).
T cells can be re-directed against speciﬁc antigens. After gene
transfer, autologous T cells express a chimeric antigen receptor
(CAR), which enables the T cell to destroy target cells. Mesothelin-
speciﬁc re-directed T cells were developed and showed in vitro and
in vivo activities [105, 106]. To achieve transient expression, the
plasmid with the gene sequence of the CAR was transferred in the
T cells by electroporation [107]. Mesothelin-speciﬁc re-directed
T cells are tested in early clinical trials (Table 2). An alternative
target in malignant mesothelioma is the ﬁbroblast activation
protein (FAP) [108, 109]. FAP-speciﬁc re-directed T cells demon-
strated antigen-speciﬁc activity in vitro and in vivo and are close to
early clinical investigation (Table 2) [108, 110]. In this clinical trial,
the adoptive transfer is planned to be carried out into the pleural
effusion to overcome blocked T-cell trafﬁcking [111].
discussion
In contrast to lung cancer, oncogenic driver mutations are absent
in malignant mesothelioma. The development of targeted
therapy therefore hinges on the exploration of pathways indirectly
activated by the loss of tumor suppressor genes or targets asso-
ciated with the disease phenotype. Efforts of targeting angiogen-
esis and cancer-associated receptor tyrosine kinases have shown
disappointing results despite the enrollment of hundreds of
mesothelioma patients in clinical trials. HDAC and proteasome
inhibitors were found to be inactive. The promising avenues for
targeted therapies in mesothelioma include the functional conse-
quences of alterations in NF2/Hippo pathway, and immunothera-
peutic approaches. The inactivation of NF-2 and resulting merlin
deﬁciency leads to a signiﬁcantly increased activity of several
pathways, including the hedgehog pathway, the activity of the
focal adhesion kinase (FAK) and the PI3K/mTOR pathway.
Inhibition of these pathways resulted in reproducible growth re-
duction of mesothelioma in preclinical models. Phase I trials in
mesothelioma demonstrated clinical activity of FAK and of PI3K/
mTOR inhibitors and a randomized phase II trial of the FAK in-
hibitor defactinib as maintenance therapy after chemotherapy has
been initiated. In regard to immunotherapeutic approaches the
jury is still out. However, based on early results in nonsmall-cell
lung cancer and other solid tumors, it appears likely that immune
checkpoint inhibitors will ﬁnd a place in the therapy of meso-
thelioma.
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Should docetaxel be standard of care for patients
with metastatic hormone-sensitive prostate cancer?
Pro and contra
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Following the results of the TAX-327 study, questions have been raised as to whether administering chemotherapy to
men with prostate cancer before symptomatic disease progression when receiving standard hormonal treatment can
improve the duration and quality of patient survival. The GETUG-AFU-15 and CHAARTED studies both assessed the
efﬁcacy and tolerability of androgen deprivation therapy (ADT) with or without docetaxel in men with metastatic hormone-
naive prostate cancer. Both studies included a mix of patients with de novo metastatic disease (∼75%) and patients who
developed metastases following treatment of localized disease. A short course of ADT was allowed in both trials prior to
accrual. Key differences between the two studies include the number of patients with high-volume metastases (GETUG-
AFU-15: 52%; CHAARTED: 65%) and number of docetaxel cycles (GETUG-AFU-15: up to nine cycles; CHAARTED six
cycles). Both studies reported an improvement in progression-free survival with docetaxel plus ADT versus ADT alone.
The GETUG-AFU-15 did not ﬁnd a signiﬁcant difference in the primary end point of overall survival (OS) {hazard ratio (HR)
0.9 [95% conﬁdence interval (CI) 0.7–1.2]; P = 0.44} for ADT plus docetaxel versus ADT alone. The CHAARTED study
met the primary end point of OS [HR 0.61 (95% CI 0.47–0.80); P = 0.0003], and in a subset analysis reported the greatest
improvement in OS for patients with high-volume disease [HR 0.60 (95% CI 0.45–0.81); P = 0.0006]. The following article
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